Orzeyful (oveporexton) for Narcolepsy type 1
What the FDA decided
The FDA approved Takeda's NDA for Orzeyful (oveporexton) in Narcolepsy type 1. First medicine to treat the orexin deficiency that causes narcolepsy type 1, rather than managing symptoms.
Who this decision matters to
Narcolepsy type 1 is a chronic neurologic disorder caused by loss of hypocretin-producing neurons, resulting in severe daytime somnolence and cataplexy. HLA-DQB1*0602 association and brain imaging support the autoimmune hypothesis. Medications enhance wakefulness; behavioral approaches optimize quality of life.
Prevalence: 1 in 2,000 to 3,000 people; often undiagnosed. See our full Narcolepsy Type 1 page for current treatments, recruiting trials, and community resources.
Where Narcolepsy Type 1 treatment stands today
Medications enhancing central nervous system wakefulness form the foundation of therapy: stimulants including modafinil (first-line), armodafinil, methylphenidate, and amphetamine derivatives manage excessive daytime sleepiness. Sodium oxybate (GHB) addresses both EDS and cataplexy and improves nighttime sleep; it is the most effective agent for cataplexy but requires careful dosing and patient education. Pitolisant, a histamine H3-receptor antagonist, offers an alternative mechanism for both EDS and cataplexy and is gaining clinical adoption. Selective serotonin or norepinephrine reuptake inhibitors (SSRIs/SNRIs) manage cataplexy alone. In August 2026 the FDA approved oveporexton (Orzeyful), a twice-daily orexin receptor 2 agonist and the first medicine to directly target the loss of orexin signaling behind narcolepsy type 1, for adults. It can be sold only after the DEA completes controlled substance scheduling, which Takeda expected by November 2026. Behavioral strategies including scheduled naps (10-20 minutes), strict sleep hygiene, avoidance of sedating medications, and comprehensive safety measures optimize quality of life. Clinical trials investigating immune-based therapies targeting HLA-DQB1*0602 or hypocretin neuron antibodies are underway. Genetic counseling helps families understand disease mechanism and inheritance patterns. Work with sleep medicine specialists experienced in narcolepsy management.
Meanwhile, 23 Narcolepsy Type 1 trials are recruiting
Whatever the FDA decides here, research on Narcolepsy Type 1 does not stop. A few currently enrolling studies, US sites first:
Other drugs Trial Friend tracks for Narcolepsy Type 1
Get notified when new narcolepsy-type-1 trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Orzeyful?
The FDA has already decided: the application was approved. See the outcome details above.
What is Orzeyful being reviewed for?
Takeda submitted a NDA for Orzeyful in Narcolepsy type 1. First medicine to treat the orexin deficiency that causes narcolepsy type 1, rather than managing symptoms.
What happens after the Orzeyful decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Takeda press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.